Cargando…

Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer

SIMPLE SUMMARY: Chemotherapy before surgery (NAC) is an option for high-risk breast cancer (BC) patients. Pathologic complete response (pCR) predicts long-term outcome and has become a surrogate biomarker for survival. pCR is, however, reached in only <10% of hormone-receptor-positive (ER+) patie...

Descripción completa

Detalles Bibliográficos
Autor principal:	Tribukait, Bernhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582392/ https://www.ncbi.nlm.nih.gov/pubmed/34771604 http://dx.doi.org/10.3390/cancers13215442

Ejemplares similares

Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume
por: Tribukait, Bernhard
Publicado: (2020)

Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer
por: Lundgren, Per‐Olof, et al.
Publicado: (2022)

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
por: Matikas, A., et al.
Publicado: (2021)

Investigation on Cell Proliferation with a New Antibody against Thymidine Kinase 1
por: Wang, Naining, et al.
Publicado: (2001)

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer
por: Toi, M, et al.
Publicado: (2004)

Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer
por: Tribukait, Bernhard, et al.
Publicado: (2023)

Serum thymidine kinase in acute leukaemia.
por: Hagberg, H., et al.
Publicado: (1984)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Thymidine kinase in breast cancer.
por: Robertson, J. F., et al.
Publicado: (1990)

THYMIDINE TRIPHOSPHATE SYNTHESIS IN TETRAHYMENA : I. Studies on Thymidine Kinase
por: Shoup, G. D., et al.
Publicado: (1966)

INDUCIBILITY OF THYMIDINE KINASE BY THYMIDINE AS A FUNCTION OF INTERPHASE STAGE
por: Hotta, Yasuo, et al.
Publicado: (1965)

Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.
por: McKenna, P. G., et al.
Publicado: (1988)

Predictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy
por: ÇAVDAR, Eyyüp, et al.
Publicado: (2022)

Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer
por: CHEN, FEIYU, et al.
Publicado: (2013)

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
por: Bagegni, Nusayba, et al.
Publicado: (2017)

Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer
por: Carlsson, Lena, et al.
Publicado: (2009)

Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer
por: Luo, Jingqin, et al.
Publicado: (2010)

3'-Amino thymidine affinity matrix for the purification of herpes simplex virus thymidine kinase.
por: Tung, P. P., et al.
Publicado: (1996)

Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival
por: Okano, Maiko, et al.
Publicado: (2019)

Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy
por: Vignoli, Alessia, et al.
Publicado: (2020)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use
por: Endo, Yuka, et al.
Publicado: (2022)

Comparison of plasma and tissue thymidine kinase activities.
por: Calvert, R. J., et al.
Publicado: (1989)

Quaternary structure of vaccinia virus thymidine kinase
por: Black, Margaret E., et al.
Publicado: (1990)

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
por: Larsson, Anna-Maria, et al.
Publicado: (2020)

ACQUISITION OF CHICK CYTOSOL THYMIDINE KINASE ACTIVITY BY THYMIDINE KINASE-DEFICIENT MOUSE FIBROBLAST CELLS AFTER FUSION WITH CHICK ERYTHROCYTES
por: Kit, Saul, et al.
Publicado: (1974)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
por: Chen, Hai-long, et al.
Publicado: (2023)

ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors
por: Dumont, Aurélie, et al.
Publicado: (2015)

Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
por: Zarotti, Cristina, et al.
Publicado: (2022)

Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy
por: Zhu, Teng, et al.
Publicado: (2017)

A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer
por: Tan, Weige, et al.
Publicado: (2016)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
por: Ding, Yuqin, et al.
Publicado: (2020)

Estrogen-Mediated Upregulation of Noxa Is Associated with Cell Cycle Progression in Estrogen Receptor-Positive Breast Cancer Cells
por: Liu, Wensheng, et al.
Publicado: (2011)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Inactive-to-Active Transition of Human Thymidine Kinase 1 Revealed by Molecular Dynamics Simulations
por: Makurat, Samanta, et al.
Publicado: (2021)

Quaternary structures of recombinant, cellular, and serum forms of Thymidine Kinase 1 from dogs and humans
por: Hanan, Sharif, et al.
Publicado: (2012)

Is serum thymidine kinase 1 a prognostic biomarker in primary tumor location of colorectal carcinomas?
por: Fang, Yujing, et al.
Publicado: (2023)

Retrospective natural history of thymidine kinase 2 deficiency
por: Garone, Caterina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v6g5gsjg226nqm5mg88i8pnr77